XML 35 R24.htm IDEA: XBRL DOCUMENT v3.6.0.2
Commitments and Contingencies (Details Textual) - USD ($)
 9 Months Ended
May 06, 2016
Dec. 29, 2015
Jun. 30, 2016
Sep. 30, 2015
Commitments and Contingencies (Textual)        
Amount received from BriVision     $ 6,500,000 $ 22,517
Collaborative Arrangement [Member]        
Commitments and Contingencies (Textual)        
Description of payment settlement schedule    
 ●upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
   
 ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
 ●upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
   
 ●upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
  
Amount received from BriVision   $ 100,000,000    
Upfront payments     $ 3,500,000  
Percentage of payments under collaborative agreement     3.50%  
Milestone payments to BioLite in cash $ 2,600,000      
Common stock newly issued, value $ 900,000      
Common stock newly issued, shares 562,500      
Share price $ 1.60      
Licensing rights   $ 3,500,000 $ 10,000,000  
Accounts payable     $ 3,500,000  
Licensing rights, term     10 years  
Collaborative Arrangement One [Member]        
Commitments and Contingencies (Textual)        
Upfront payments     $ 6,500,000  
Percentage of payments under collaborative agreement     6.50%  
Accounts payable     $ 6,500,000